PT2286825T - Ligandos do recetor de melanocortina - Google Patents

Ligandos do recetor de melanocortina

Info

Publication number
PT2286825T
PT2286825T PT101825669T PT10182566T PT2286825T PT 2286825 T PT2286825 T PT 2286825T PT 101825669 T PT101825669 T PT 101825669T PT 10182566 T PT10182566 T PT 10182566T PT 2286825 T PT2286825 T PT 2286825T
Authority
PT
Portugal
Prior art keywords
receptor ligands
melanocortin receptor
melanocortin
ligands
receptor
Prior art date
Application number
PT101825669T
Other languages
English (en)
Inventor
Xin Dong Zheng
Moreau Jacques-Pierre
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of PT2286825T publication Critical patent/PT2286825T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
PT101825669T 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina PT2286825T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69777905P 2005-07-08 2005-07-08
US74885005P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
PT2286825T true PT2286825T (pt) 2017-01-02

Family

ID=37637790

Family Applications (4)

Application Number Title Priority Date Filing Date
PT172028367T PT3354273T (pt) 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina
PT101825669T PT2286825T (pt) 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina
PT121887848T PT2548568T (pt) 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina
PT10170694T PT2236151E (pt) 2005-07-08 2006-07-10 Ligandos do receptor de melanocortina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT172028367T PT3354273T (pt) 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT121887848T PT2548568T (pt) 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina
PT10170694T PT2236151E (pt) 2005-07-08 2006-07-10 Ligandos do receptor de melanocortina

Country Status (21)

Country Link
US (8) US8039435B2 (pt)
EP (6) EP3354273B1 (pt)
JP (4) JP4734411B2 (pt)
KR (2) KR101232201B1 (pt)
CN (4) CN101676298A (pt)
AU (2) AU2006269261B2 (pt)
CA (4) CA3228910A1 (pt)
DK (4) DK2236151T3 (pt)
ES (4) ES2663916T3 (pt)
FR (1) FR21C1060I2 (pt)
HK (2) HK1149190A1 (pt)
HU (4) HUE037147T2 (pt)
IL (3) IL188545A (pt)
NL (1) NL301150I2 (pt)
NZ (2) NZ565217A (pt)
PL (4) PL2236151T3 (pt)
PT (4) PT3354273T (pt)
RU (2) RU2439079C2 (pt)
SG (1) SG163585A1 (pt)
SI (1) SI3354273T1 (pt)
WO (1) WO2007008704A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007020152A1 (de) * 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
RU2453328C2 (ru) * 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
TR201903610T4 (tr) 2008-05-27 2019-03-21 Genzyme Corp Alfa-melanosit uyarici hormonlarin peptid analoglari.
WO2009152079A1 (en) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
KR101726893B1 (ko) 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
RU2012108110A (ru) * 2009-08-05 2013-09-10 Ипсен Фарма С.А.С. Применение меланокортинов для лечения дислипидемии
HUE031856T2 (en) * 2009-08-31 2017-08-28 Tensive Controls Inc Stabilized melanocortin ligands
WO2011060355A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2
RU2548753C2 (ru) * 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Фармацевтические композиции лигандов рецепторов меланокортинов
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
MX2012005862A (es) 2009-11-23 2012-09-07 Palatin Technologies Inc Peptidos ciclicos especificos del receptor de melanocortina-1.
WO2012172433A2 (en) 2011-06-14 2012-12-20 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
HRP20211950T1 (hr) 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
DK2722340T3 (en) 2012-10-19 2015-06-08 Txp Pharma Gmbh Alpha- and gamma-MSH analogues
US10232018B2 (en) 2013-03-14 2019-03-19 Mallinckrodt Ard Ip Limited ACTH for treatment of acute respiratory distress syndrome
RU2019116003A (ru) * 2013-03-15 2019-07-17 Ритм Фармасьютикалз, Инк. Фармацевтические композиции
CN118240012A (zh) * 2013-03-15 2024-06-25 节奏制药公司 肽组合物
HUE052977T2 (hu) 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
SG10202101510XA (en) * 2015-09-30 2021-03-30 Rhythm Pharmaceuticals Inc Method of treating melanocortin-4 receptor pathway-associated disorders
WO2017066754A1 (en) * 2015-10-15 2017-04-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for the treatment of depression and anxiety
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
US20190255142A1 (en) * 2016-10-17 2019-08-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
JP2020514365A (ja) * 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス メラノコルチン４受容体に結合可能な二環式化合物
US20210169969A1 (en) 2018-04-06 2021-06-10 Leonardus H.T. Van Der Ploeg Compositions for treating kidney disease
WO2019219714A1 (en) * 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
AU2019273132A1 (en) * 2018-05-23 2020-12-17 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
MX2023003360A (es) * 2020-09-24 2023-06-23 Rhythm Pharmaceuticals Inc Metodos de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.
WO2022251650A1 (en) * 2021-05-27 2022-12-01 The Regents Of The University Of Michigan Mc3r agonist peptides
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613874A (en) 1898-11-08 George e
US1613874A (en) 1922-03-29 1927-01-11 Miner Inc W H Friction draft gear
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
SE9700620D0 (sv) 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
WO1999055679A1 (en) 1998-04-28 1999-11-04 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
MXPA01001100A (es) * 1998-07-27 2002-08-20 Univ Iowa State Res Found Inc Gen del receptor melanocortina-4 y su uso como un marcador genetico para contenido de grasa, ganacia de peso y7o consumo de alimento para animales.
EP1119252A4 (en) 1998-08-21 2004-03-03 Childrens Medical Center USE OF MELANIN FOR INHIBITING ANGIOGENESIS AND MACULAR DEGENERATION
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
KR100558131B1 (ko) * 1999-03-29 2006-03-10 더 프록터 앤드 갬블 캄파니 멜라노코르틴 수용체 리간드를 함유하는 약제학적 조성물및 멜라노코르틴 수용체 리간드를 함유하는 약제의제조방법
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
ATE409410T1 (de) 1999-11-12 2008-10-15 Merck & Co Inc Zellen mit defizientem melanocortin-3-rezeptor, transgene mäuse und verfahren zur auswahl von substanzen, die das körpergewicht regulieren können
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
IL152781A0 (en) * 2000-06-28 2003-06-24 Pfizer Prod Inc Melanocortin receptor ligands
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MXPA03002160A (es) 2000-09-13 2004-05-04 Eleanor Roosevelt Inst Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
WO2002079146A2 (en) 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
JP2004534851A (ja) * 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． メラノコルチン受容体に特異的な線状および環状ペプチド
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US20040128136A1 (en) * 2002-09-20 2004-07-01 Irani Pourang Polad Internet voice browser
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
WO2005000339A2 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
AU2004267044B8 (en) 2003-08-20 2009-12-17 Emisphere Technologies, Inc. Compounds, methods and formulations for the oral delivery of a glucagon like peptide (GLP)-1 compound or an melanocortin 4 receptor (MC4) agonist peptide
CA2532026C (en) 2003-08-20 2012-04-17 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
WO2005040109A1 (en) * 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
EP1694348A4 (en) 2003-12-10 2009-07-01 Merck & Co Inc VOLUNTARY INHIBITION OF CONSUMPTION OF ETHANOL USING MELANOCORTIN RECEPTOR 4 RECEPTOR AGONISTS
US20070123453A1 (en) 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
WO2006037188A1 (en) 2004-10-08 2006-04-13 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
WO2006073772A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
NZ566489A (en) 2005-08-26 2008-10-31 Action Pharma As Therapeutically active alpha-MSH analogues

Also Published As

Publication number Publication date
AU2009230799A1 (en) 2009-11-19
PT2236151E (pt) 2012-07-02
US20200095281A1 (en) 2020-03-26
CN101257916B (zh) 2013-04-03
EP1915167A2 (en) 2008-04-30
NZ580806A (en) 2012-07-27
PL2236151T3 (pl) 2012-10-31
US20180305406A1 (en) 2018-10-25
EP2236151B1 (en) 2012-05-23
EP3354273B1 (en) 2021-03-24
PT3354273T (pt) 2021-06-28
AU2009230799B2 (en) 2012-02-09
DK2236151T3 (da) 2012-07-09
CA2793119A1 (en) 2007-01-18
IL188545A0 (en) 2008-04-13
HUE055154T2 (hu) 2021-11-29
KR20080049711A (ko) 2008-06-04
WO2007008704A2 (en) 2007-01-18
US8039435B2 (en) 2011-10-18
PL3354273T3 (pl) 2021-10-11
EP2548568A2 (en) 2013-01-23
EP2548568B1 (en) 2018-01-10
DK3354273T3 (da) 2021-06-28
JP2009500427A (ja) 2009-01-08
KR101232201B1 (ko) 2013-02-12
CN105837661A (zh) 2016-08-10
CA2793119C (en) 2019-07-23
PL2548568T3 (pl) 2018-06-29
HUE031731T2 (en) 2017-07-28
KR20100016120A (ko) 2010-02-12
RU2009131092A (ru) 2011-02-20
HUS2100054I1 (hu) 2021-12-28
US20160368962A1 (en) 2016-12-22
EP2286825A3 (en) 2011-07-27
EP3925614A2 (en) 2021-12-22
RU2008104803A (ru) 2009-08-20
US20170240595A1 (en) 2017-08-24
PL2286825T3 (pl) 2017-06-30
EP3925614A3 (en) 2022-03-23
CN101676298A (zh) 2010-03-24
IL201732A (en) 2016-07-31
US9850280B2 (en) 2017-12-26
SI3354273T1 (sl) 2021-10-29
EP2548568A3 (en) 2013-07-17
FR21C1060I1 (fr) 2022-01-21
CA3044795A1 (en) 2007-01-18
ES2663916T3 (es) 2018-04-17
JP2010090130A (ja) 2010-04-22
DK2286825T3 (en) 2017-01-09
CA3228910A1 (en) 2007-01-18
EP2286825B1 (en) 2016-09-28
US20220127305A1 (en) 2022-04-28
US20110183886A1 (en) 2011-07-28
IL188545A (en) 2011-08-31
NZ565217A (en) 2010-03-26
JP5889513B2 (ja) 2016-03-22
CA2614615A1 (en) 2007-01-18
CN103755786B (zh) 2016-05-11
HK1149190A1 (en) 2011-09-30
AU2006269261A1 (en) 2007-01-18
US20180105557A1 (en) 2018-04-19
CN101257916A (zh) 2008-09-03
HUE037147T2 (hu) 2018-08-28
WO2007008704A3 (en) 2007-10-11
EP2286825A2 (en) 2011-02-23
KR100997177B1 (ko) 2010-11-29
EP2236151A1 (en) 2010-10-06
EP3354273A1 (en) 2018-08-01
IL246392A (en) 2017-07-31
NL301150I1 (pt) 2021-12-08
US20100279922A1 (en) 2010-11-04
JP2013253090A (ja) 2013-12-19
SG163585A1 (en) 2010-08-30
NL301150I2 (nl) 2022-11-24
IL201732A0 (en) 2010-06-16
US9458195B2 (en) 2016-10-04
JP5965520B2 (ja) 2016-08-03
PT2548568T (pt) 2018-03-21
FR21C1060I2 (fr) 2022-12-02
ES2877349T3 (es) 2021-11-16
RU2380372C2 (ru) 2010-01-27
CN103755786A (zh) 2014-04-30
JP2015232003A (ja) 2015-12-24
ES2386862T3 (es) 2012-09-03
ES2604328T3 (es) 2017-03-06
JP4734411B2 (ja) 2011-07-27
RU2439079C2 (ru) 2012-01-10
CA2614615C (en) 2012-10-16
EP1915167A4 (en) 2010-04-07
HK1258965A1 (zh) 2019-11-22
AU2006269261B2 (en) 2009-12-17
DK2548568T3 (en) 2018-03-12

Similar Documents

Publication Publication Date Title
HUS2100054I1 (hu) Melanokortin receptor ligandumok
IL188544A0 (en) Ligands of melanocortin receptors
EP1872421A4 (en) MEANS FOR CONNECTING TERMINALS
GB0505941D0 (en) Human-to-mobile interfaces
ZA200801743B (en) Intermediate bracket
IL189265A0 (en) Ferrocene-diphosphine ligands
EP1869271A4 (en) SUPPORT
GB0624987D0 (en) Novel aminoguanidines as melanocortin receptor ligands
GB0613762D0 (en) Slabline structure
GB0516946D0 (en) Receptor
GB0602684D0 (en) Bracket
GB2418125B (en) Saddle cover
GB0521122D0 (en) Mat
GB0522484D0 (en) Receptor
GB0510253D0 (en) Receptor
GB0522394D0 (en) Receptor
GB0522077D0 (en) Receptor
GB0519308D0 (en) Bracket
AU307179S (en) Bracket
AU305163S (en) Bracket
AU305162S (en) Bracket
GB0514990D0 (en) Mats
TWM291769U (en) Ant-slip mat
GB0516849D0 (en) Attachment means
GB0506820D0 (en) Saddles